Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy

• Published in: Scientific reports Vol. 11; no. 1; p. 2735
• Main Authors: Chi, Sheng-Chu, Kang, Yi-No, Huang, Yi-Ming
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 02-02-2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/699/3161/3175; 692/699/3161/3178; Bias; Clinical trials; Diabetic retinopathy; Growth factors; Hospitals; Humanities and Social Sciences; Meta-analysis; multidisciplinary; Patients; Science; Science (multidisciplinary); Systematic review; Vascular diseases; Vascular endothelial growth factor
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-82316-y

Polypoidal choroidal vasculopathy (PCV) is a vision-threatening disease common in Asian populations. However, the optimal treatment for PCV remains under debate. We searched the databases with optimal searching strategy. The study included randomized clinical trials and prospective studies that recruited patients with active PCV who had received interventions, including PDT, anti-VEGF, or a combination of PDT and anti-VEGF. The Grading of Recommendations Assessment, Development, and Evaluation methodology was used for rating the quality of evidence. Our study included 11 studies involving 1277 patients. The network meta-analysis of RCTs revealed the anti-VEGF group, early combination group, and late combination group had significant BCVA changes compared with the PDT group. Early combination therapy led to a significant decrease in CRT compared with PDT, anti-VEGF, and late combination therapy. Additionally, the early combination group had a significantly higher complete polyp regression rate than the anti-VEGF group. No significant differences were detected in the analysis of the number of anti-VEGF injections and safety profile. This network meta-analysis revealed that early combination therapy exhibited better efficacy related to anatomical outcomes than other therapies. Nonetheless, no significant differences related to BCVA change could be detected between anti-VEGF and late combination therapy.